Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib

Disha Dumka, Poonam Puri, Nathalie Carayol, Crystal Lumby, Harikrishnan Balachandran, Katja Schuster, Amit K. Verma, Lance S. Terada, Leonidas C. Platanias, Simrit Parmar

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Dasatinib, a dual Src/Abl tyrosine kinase inhibitor, has significant antileukemic effects against various imatinib mesylate-resistant BCR/ABL mutants. Despite well-documented inhibitory effects of dasatinib on BCR/ABL kinase, the exact downstream cellular events leading to generation of its potent antileukemic effects remain to be defined. We provide evidence that p38 Map kinase (MAPK) pathway is activated leading to increased upregulation of mixed lineage kinase 3, MKK3/6, MSK1, and Mapkapk2, upon treatment of BCR/ABL expressing cells with dasatinib, including cells expressing various imatinib-resistant mutants, except for T315I. Our data demonstrate that such dasatinib-dependent activation of p38 MAPK and its effectors plays a critical role in the generation of antileukemic responses, since pharmacological inhibition of p38 or siRNA-mediated knockdown of its expression reverse dasatinib-mediated apoptosis, cell cycle arrest, and anti-proliferative effects. p38 MAPK inhibition also reversed dasatinib-induced suppression of CML patient-derived leukemic colony-forming units progenitor growth in vitro, as well as BCR/ABL expressing KT-1 cell-derived leukemic progenitor growth. Altogether, our findings suggest a critical role for p38 MAPK pathway in the generation of antileukemic effects of dasatinib, and raise the possibility that development of novel means to enhance p38 MAPK activation in BCR/ABL expressing cells may be an approach to promote antileukemic responses and, possibly, reverse T315I mutation-mediated resistance.

Original languageEnglish (US)
Pages (from-to)2017-2029
Number of pages13
JournalLeukemia and Lymphoma
Volume50
Issue number12
DOIs
StatePublished - Dec 2009

Fingerprint

MAP Kinase Signaling System
Phosphotransferases
KT 1
Cohort Effect
src-Family Kinases
Growth
Cell Cycle Checkpoints
Dasatinib
Small Interfering RNA
Up-Regulation
Stem Cells
Pharmacology
Apoptosis
Mutation

Keywords

  • CML
  • Dasatinib
  • P38 Map kinase

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Dumka, D., Puri, P., Carayol, N., Lumby, C., Balachandran, H., Schuster, K., ... Parmar, S. (2009). Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Leukemia and Lymphoma, 50(12), 2017-2029. https://doi.org/10.3109/10428190903147637

Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. / Dumka, Disha; Puri, Poonam; Carayol, Nathalie; Lumby, Crystal; Balachandran, Harikrishnan; Schuster, Katja; Verma, Amit K.; Terada, Lance S.; Platanias, Leonidas C.; Parmar, Simrit.

In: Leukemia and Lymphoma, Vol. 50, No. 12, 12.2009, p. 2017-2029.

Research output: Contribution to journalArticle

Dumka, D, Puri, P, Carayol, N, Lumby, C, Balachandran, H, Schuster, K, Verma, AK, Terada, LS, Platanias, LC & Parmar, S 2009, 'Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib', Leukemia and Lymphoma, vol. 50, no. 12, pp. 2017-2029. https://doi.org/10.3109/10428190903147637
Dumka, Disha ; Puri, Poonam ; Carayol, Nathalie ; Lumby, Crystal ; Balachandran, Harikrishnan ; Schuster, Katja ; Verma, Amit K. ; Terada, Lance S. ; Platanias, Leonidas C. ; Parmar, Simrit. / Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. In: Leukemia and Lymphoma. 2009 ; Vol. 50, No. 12. pp. 2017-2029.
@article{61b5e3f3daac41278f07d6e6221cd34e,
title = "Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib",
abstract = "Dasatinib, a dual Src/Abl tyrosine kinase inhibitor, has significant antileukemic effects against various imatinib mesylate-resistant BCR/ABL mutants. Despite well-documented inhibitory effects of dasatinib on BCR/ABL kinase, the exact downstream cellular events leading to generation of its potent antileukemic effects remain to be defined. We provide evidence that p38 Map kinase (MAPK) pathway is activated leading to increased upregulation of mixed lineage kinase 3, MKK3/6, MSK1, and Mapkapk2, upon treatment of BCR/ABL expressing cells with dasatinib, including cells expressing various imatinib-resistant mutants, except for T315I. Our data demonstrate that such dasatinib-dependent activation of p38 MAPK and its effectors plays a critical role in the generation of antileukemic responses, since pharmacological inhibition of p38 or siRNA-mediated knockdown of its expression reverse dasatinib-mediated apoptosis, cell cycle arrest, and anti-proliferative effects. p38 MAPK inhibition also reversed dasatinib-induced suppression of CML patient-derived leukemic colony-forming units progenitor growth in vitro, as well as BCR/ABL expressing KT-1 cell-derived leukemic progenitor growth. Altogether, our findings suggest a critical role for p38 MAPK pathway in the generation of antileukemic effects of dasatinib, and raise the possibility that development of novel means to enhance p38 MAPK activation in BCR/ABL expressing cells may be an approach to promote antileukemic responses and, possibly, reverse T315I mutation-mediated resistance.",
keywords = "CML, Dasatinib, P38 Map kinase",
author = "Disha Dumka and Poonam Puri and Nathalie Carayol and Crystal Lumby and Harikrishnan Balachandran and Katja Schuster and Verma, {Amit K.} and Terada, {Lance S.} and Platanias, {Leonidas C.} and Simrit Parmar",
year = "2009",
month = "12",
doi = "10.3109/10428190903147637",
language = "English (US)",
volume = "50",
pages = "2017--2029",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib

AU - Dumka, Disha

AU - Puri, Poonam

AU - Carayol, Nathalie

AU - Lumby, Crystal

AU - Balachandran, Harikrishnan

AU - Schuster, Katja

AU - Verma, Amit K.

AU - Terada, Lance S.

AU - Platanias, Leonidas C.

AU - Parmar, Simrit

PY - 2009/12

Y1 - 2009/12

N2 - Dasatinib, a dual Src/Abl tyrosine kinase inhibitor, has significant antileukemic effects against various imatinib mesylate-resistant BCR/ABL mutants. Despite well-documented inhibitory effects of dasatinib on BCR/ABL kinase, the exact downstream cellular events leading to generation of its potent antileukemic effects remain to be defined. We provide evidence that p38 Map kinase (MAPK) pathway is activated leading to increased upregulation of mixed lineage kinase 3, MKK3/6, MSK1, and Mapkapk2, upon treatment of BCR/ABL expressing cells with dasatinib, including cells expressing various imatinib-resistant mutants, except for T315I. Our data demonstrate that such dasatinib-dependent activation of p38 MAPK and its effectors plays a critical role in the generation of antileukemic responses, since pharmacological inhibition of p38 or siRNA-mediated knockdown of its expression reverse dasatinib-mediated apoptosis, cell cycle arrest, and anti-proliferative effects. p38 MAPK inhibition also reversed dasatinib-induced suppression of CML patient-derived leukemic colony-forming units progenitor growth in vitro, as well as BCR/ABL expressing KT-1 cell-derived leukemic progenitor growth. Altogether, our findings suggest a critical role for p38 MAPK pathway in the generation of antileukemic effects of dasatinib, and raise the possibility that development of novel means to enhance p38 MAPK activation in BCR/ABL expressing cells may be an approach to promote antileukemic responses and, possibly, reverse T315I mutation-mediated resistance.

AB - Dasatinib, a dual Src/Abl tyrosine kinase inhibitor, has significant antileukemic effects against various imatinib mesylate-resistant BCR/ABL mutants. Despite well-documented inhibitory effects of dasatinib on BCR/ABL kinase, the exact downstream cellular events leading to generation of its potent antileukemic effects remain to be defined. We provide evidence that p38 Map kinase (MAPK) pathway is activated leading to increased upregulation of mixed lineage kinase 3, MKK3/6, MSK1, and Mapkapk2, upon treatment of BCR/ABL expressing cells with dasatinib, including cells expressing various imatinib-resistant mutants, except for T315I. Our data demonstrate that such dasatinib-dependent activation of p38 MAPK and its effectors plays a critical role in the generation of antileukemic responses, since pharmacological inhibition of p38 or siRNA-mediated knockdown of its expression reverse dasatinib-mediated apoptosis, cell cycle arrest, and anti-proliferative effects. p38 MAPK inhibition also reversed dasatinib-induced suppression of CML patient-derived leukemic colony-forming units progenitor growth in vitro, as well as BCR/ABL expressing KT-1 cell-derived leukemic progenitor growth. Altogether, our findings suggest a critical role for p38 MAPK pathway in the generation of antileukemic effects of dasatinib, and raise the possibility that development of novel means to enhance p38 MAPK activation in BCR/ABL expressing cells may be an approach to promote antileukemic responses and, possibly, reverse T315I mutation-mediated resistance.

KW - CML

KW - Dasatinib

KW - P38 Map kinase

UR - http://www.scopus.com/inward/record.url?scp=72949116167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72949116167&partnerID=8YFLogxK

U2 - 10.3109/10428190903147637

DO - 10.3109/10428190903147637

M3 - Article

VL - 50

SP - 2017

EP - 2029

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 12

ER -